Liquidia (NASDAQ:LQDA) CAO Dana Boyle Sells 9,002 Shares

Liquidia Corporation (NASDAQ:LQDA) CAO Dana Boyle sold 9,002 shares of the business’s stock in a transaction dated Monday, July 13th. The stock was sold at an average price of $71.51, for a total transaction of $643,733.02. Following the sale, the chief accounting officer directly owned 169,519 shares in the company, valued at $12,122,303.69. The trade was a 5.04% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dana Boyle also recently made the following trade(s):

• On Monday, April 27th, Dana Boyle sold 1,576 shares of Liquidia stock. The stock was sold at an average price of $37.78, for a total transaction of $59,541.28.

Liquidia Price Performance

Shares of NASDAQ LQDA opened at $76.49 on Wednesday. Liquidia Corporation has a fifty-two week low of $14.04 and a fifty-two week high of $82.96. The company has a 50 day simple moving average of $66.37 and a two-hundred day simple moving average of $47.52. The company has a market capitalization of $6.80 billion, a price-to-earnings ratio of 546.40 and a beta of 0.55. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.03 and a current ratio of 2.22.

Liquidia (NASDAQ:LQDA) last released its earnings results on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.11. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The firm had revenue of $132.87 million during the quarter, compared to analyst estimates of $119.44 million. The firm’s revenue was up 4187.1% compared to the same quarter last year. Analysts expect that Liquidia Corporation will post 3.02 EPS for the current fiscal year.

Liquidia News Summary

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Recent commentary notes that Liquidia’s Yutrepia has had a strong commercial debut, suggesting early traction in its pulmonary arterial hypertension market opportunity. Can LQDA’s Yutrepia Drive Growth in the Competitive PAH Market?
• Neutral Sentiment: An investor letter from Laughing Water Capital mentioned Liquidia in a broader portfolio update, but did not provide a clear company-specific catalyst. Here’s Laughing Water Capital’s Updates on Liquidia Corp. (LQDA)
• Negative Sentiment: Multiple insiders, including the CEO, CFO, general counsel, and other executives, sold shares on July 13 in pre-arranged 10b5-1 transactions tied to tax withholding from vesting equity awards. While these sales were planned and not necessarily a bearish signal, the size and breadth of the sales may still pressure investor sentiment. SEC filing – Roger Jeffs sale

Institutional Trading of Liquidia

A number of hedge funds have recently bought and sold shares of the company. GSA Capital Partners LLP boosted its holdings in shares of Liquidia by 63.6% in the fourth quarter. GSA Capital Partners LLP now owns 63,176 shares of the company’s stock worth $2,179,000 after buying an additional 24,555 shares during the last quarter. Farallon Capital Management LLC increased its holdings in Liquidia by 102.1% during the third quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock valued at $194,783,000 after buying an additional 4,326,876 shares during the last quarter. Tudor Investment Corp ET AL purchased a new stake in Liquidia during the third quarter valued at approximately $1,536,000. State of New Jersey Common Pension Fund D bought a new position in Liquidia in the fourth quarter worth approximately $709,000. Finally, Caprock Group LLC raised its position in Liquidia by 9.3% in the fourth quarter. Caprock Group LLC now owns 1,783,921 shares of the company’s stock worth $61,527,000 after acquiring an additional 151,832 shares during the period. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. Raymond James Financial reissued a “strong-buy” rating and issued a $68.00 target price on shares of Liquidia in a report on Thursday, June 4th. Bank of America reaffirmed a “neutral” rating and issued a $79.00 price target (up from $64.00) on shares of Liquidia in a research report on Monday, June 29th. HC Wainwright upped their price target on shares of Liquidia from $67.00 to $75.00 and gave the stock a “buy” rating in a research note on Friday, June 5th. Needham & Company LLC increased their price objective on shares of Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, May 11th. Finally, Wells Fargo & Company raised their price objective on shares of Liquidia from $51.00 to $62.00 and gave the company an “overweight” rating in a research note on Tuesday, May 12th. Three equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $68.88.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).